LEXXW - Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
(TheNewswire)
Kelowna, British Columbia – TheNewswire - July 14, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms ispleased to announce the Company has been notified of the allowance ofits 26 th worldwide patent with a new patent to be granted inJapan.
This is Lexaria’s third patent to be granted inJapan, entitled LipophilicActive Agent Infused Compositions With Reduced Food Effect . This patent recognizes DehydraTECH’s ability to deliveractive pharmaceutical ingredients (“APIs”) more efficientlyregardless of the presence of foods withinthe gastrointestinal system – theso-called “ food effect ”. Delivering drugs more consistently into the bloodstreamregardless of the presence of food in the GI is an importantachievement in the quest for more reliable drug dosing.
This is the first patent issued from Lexaria’sseventh patent family and refers to tetrahydrocannabinol (“THC”). Lexaria has patents granted or patentapplications progressing in countries around the world with aggregatepopulations of nearly 4 billion people and will report on furtherprogress as information becomes available.
In additional news, Lexaria has submitted its briefingbook to the US Food and Drug Administration (“FDA”). The Companyhas no further requirements or deliverables related to thepre-Investigational New Drug (“IND”) meeting request announced on June 2,2022 . The FDA has provided a targetdate of July 30, 2022 for meeting or comments.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting more effectiveoral delivery. Since 2016, DehydraTECH has repeatedly demonstrated theability to increase bio-absorption with cannabinoids, antiviral drugs,PDE5 inhibitors and more. DehydraTECH has also evidenced an ability todeliver some drugs more effectively across the blood brain barrier.Lexaria operates a licensed in-house research laboratory and holds arobust intellectual property portfolio with 25 patents granted plusthe 26 th patent allowed; and roughly 50 patents pending worldwide.For more information, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS
This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the company relating the Company’sability to carry out research initiatives, receive regulatoryapprovals or grants or experience positive effects or results from anyresearch or study. Such forward-looking statements are estimatesreflecting the Company's best judgment based upon current informationand involve a number of risks and uncertainties, and there can be noassurance that the Company will actually achieve the plans,intentions, or expectations disclosed in these forward-lookingstatements. As such, you should not place undue reliance on theseforward-looking statements. Factors which could cause actual resultsto differ materially from those estimated by the Company include, butare not limited to, government regulation and regulatory approvals,managing and maintaining growth, the effect of adverse publicity,litigation, competition, scientific discovery, the patent applicationand approval process, potential adverse effects arising from thetesting or use of products utilizing the DehydraTECH technology, theCompany’s ability to maintain existing collaborations and realizethe benefits thereof, delays or cancellations of planned R&D thatcould occur related to pandemics or for other reasons, and otherfactors which may be identified from time to time in the Company'spublic announcements and periodic filings with the US Securities andExchange Commission on EDGAR. There is no assurance that any ofLexaria’s postulated uses, benefits, or advantages for the patentedand patent-pending technology will in fact be realized in any manneror in any part. No statement herein has been evaluated by the Food andDrug Administration (FDA). Lexaria-associated products are notintended to diagnose, treat, cure or prevent any disease. Anyforward-looking statements contained in this release speak only as ofthe date hereof, and the Company expressly disclaims any obligation toupdate any forward-looking statements contained herein, whether as aresult of any new information, future events, changed circumstances orotherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of InvestorRelations
Copyright (c) 2022 TheNewswire - All rights reserved.